Key result
Among 6 patients with fulminant giant cell myocarditis requiring mechanical circulatory support, 5 showed improved cardiac function with immunosuppressive therapy, and 3 treated with dual immunosuppressants achieved >1-year survival.
Why the study?
The therapeutic strategy for giant cell myocarditis remains controversial.
Does mechanical circulatory support combined with immunosuppression improve survival in patients with fulminant giant cell myocarditis?
Observational (n=6)
No
Does mechanical circulatory support combined with immunosuppression improve survival in patients with fulminant giant cell myocarditis?
In patients with fulminant giant cell myocarditis, early administration of cyclosporine-based immunosuppression combined with mechanical circulatory support may facilitate cardiac recovery and improve survival.
Answers are grounded in this paper and cite their sources.
May support immunosuppression with MCS for recovery in fulminant giant cell myocarditis; leaves open need for prospective validation.
BACKGROUND: The therapeutic strategy for giant cell myocarditis (GCM) remains controversial, so we reviewed the clinical status of Japanese patients with GCM. METHODS AND RESULTS: We retrospectively reviewed 6 consecutive patients with GCM requiring percutaneous mechanical circulatory support (p-MCS), with 3 further requiring ventricular assist devices. One patient died during p-MCS. Cardiac function improved in the other 5 with immunosuppressive therapy, but only 3 patients treated with dual immunosuppressants, including cyclosporine (CyA), achieved >1-year survival. CONCLUSIONS: The prognosis of patients with fulminant GCM is poor, but a treatment that combines MCS and early administration of CyA-based immunosuppressants will be useful.
No takes yet. Share an insight, caveat, or question.
Nakajima-Doi et al. (2020) conducted an observational in Giant Cell Myocarditis (n=6). Mechanical circulatory support combined with immunosuppression was evaluated on Clinical and disease outcomes (survival and cardiac function recovery). Among 6 patients with fulminant giant cell myocarditis requiring mechanical circulatory support, 5 showed improved cardiac function with immunosuppressive therapy, and 3 treated with dual immunosuppressants achieved >1-year survival.
Synapse has enriched 10 related papers. Consider them for comparative context: